Thermo Fisher Scientific Beheer
Beheer criteriumcontroles 3/4
De CEO Thermo Fisher Scientific is Marc Casper, benoemd in Oct2009, heeft een ambtstermijn van 15.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 18.98M, bestaande uit 9.1% salaris en 90.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.046% van de aandelen van het bedrijf, ter waarde $ 98.46M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5 jaar en 12.7 jaar.
Belangrijke informatie
Marc Casper
Algemeen directeur
US$19.0m
Totale compensatie
| Percentage CEO-salaris | 9.1% |
| Dienstverband CEO | 15.1yrs |
| Eigendom CEO | 0.05% |
| Management gemiddelde ambtstermijn | 5yrs |
| Gemiddelde ambtstermijn bestuur | 12.7yrs |
Recente managementupdates
Recent updates
Thermo Fisher Scientific Q3: Expecting Market Recovery In FY25; Upgrade To 'Buy'
Oct 23Thermo Fisher Scientific: Fantastic Company, Rich Valuation
Oct 04These 4 Measures Indicate That Thermo Fisher Scientific (NYSE:TMO) Is Using Debt Reasonably Well
Sep 21
Thermo Fisher Scientific Inc.'s (NYSE:TMO) Price Is Out Of Tune With Earnings
Aug 16Thermo Fisher Scientific: Microscopic Signs Of Growth Emerging
Jul 25A Look At The Fair Value Of Thermo Fisher Scientific Inc. (NYSE:TMO)
Jul 11Is Thermo Fisher Scientific (NYSE:TMO) A Risky Investment?
Jun 18Low Yield, High Growth: Unveiling The Power Of Thermo Fisher's Dividends
Jun 07Thermo Fisher: Renewed Growth Yet To Materialize, But Already Priced In (Rating Downgrade)
Apr 30Thermo Fisher Scientific Inc. (NYSE:TMO) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Apr 27Why Thermo Fisher Scientific Inc. (NYSE:TMO) Could Be Worth Watching
Apr 24Thermo Fisher Scientific: Too Hot To Handle
Apr 15Investors Still Waiting For A Pull Back In Thermo Fisher Scientific Inc. (NYSE:TMO)
Apr 02We Think Thermo Fisher Scientific (NYSE:TMO) Can Stay On Top Of Its Debt
Mar 12Thermo Fisher's Bright Future Makes It A Great Buy On Weakness
Feb 06Here's What Analysts Are Forecasting For Thermo Fisher Scientific Inc. (NYSE:TMO) After Its Yearly Results
Feb 02Thermo Fisher: Blue Chip Stock Melded With Growth Characteristics
Jan 16Thermo Fisher: Downturn In Pharma And Biotech And Weak China Growth; Initiate With 'Hold'
Jan 06Is Now An Opportune Moment To Examine Thermo Fisher Scientific Inc. (NYSE:TMO)?
Dec 29Does Thermo Fisher Scientific (NYSE:TMO) Have A Healthy Balance Sheet?
Dec 11Thermo Fisher Scientific: I Am Still Waiting For An Attractive Buying Opportunity.
Dec 02Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Could Be 25% Below Their Intrinsic Value Estimate
Nov 07Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 28 2024 | n/a | n/a | US$6b |
| Jun 29 2024 | n/a | n/a | US$6b |
| Mar 30 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$19m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jul 01 2023 | n/a | n/a | US$6b |
| Apr 01 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$28m | US$2m | US$7b |
| Oct 01 2022 | n/a | n/a | US$7b |
| Jul 02 2022 | n/a | n/a | US$7b |
| Apr 02 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$21m | US$2m | US$8b |
| Oct 02 2021 | n/a | n/a | US$9b |
| Jul 03 2021 | n/a | n/a | US$9b |
| Apr 03 2021 | n/a | n/a | US$8b |
| Dec 31 2020 | US$26m | US$2m | US$6b |
| Sep 26 2020 | n/a | n/a | US$5b |
| Jun 27 2020 | n/a | n/a | US$4b |
| Mar 28 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$19m | US$2m | US$4b |
| Sep 28 2019 | n/a | n/a | US$4b |
| Jun 29 2019 | n/a | n/a | US$4b |
| Mar 30 2019 | n/a | n/a | US$3b |
| Dec 31 2018 | US$19m | US$1m | US$3b |
| Sep 29 2018 | n/a | n/a | US$3b |
| Jun 30 2018 | n/a | n/a | US$2b |
| Mar 31 2018 | n/a | n/a | US$2b |
| Dec 31 2017 | US$22m | US$1m | US$2b |
Compensatie versus markt: De totale vergoeding ($USD 18.98M ) Marc } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.86M ).
Compensatie versus inkomsten: De vergoeding van Marc is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Marc Casper (56 yo)
15.1yrs
Tenure
US$18,976,669
Compensatie
Mr. Marc N. Casper has been the Chief Executive Officer and President of Thermo Fisher Scientific, Inc. since October 15, 2009 and has been its Chairman of the Board of Directors since February 26, 2020. M...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 15.1yrs | US$18.98m | 0.046% $ 98.5m | |
| Senior VP & CFO | 9.3yrs | US$6.24m | 0.010% $ 22.4m | |
| Executive VP & COO | 2.8yrs | US$7.25m | 0.0044% $ 9.5m | |
| Chief Human Resources Officer & Senior VP | 7.7yrs | US$2.89m | 0.0035% $ 7.5m | |
| Executive Vice President | no data | US$5.73m | 0.0044% $ 9.4m | |
| VP & Chief Accounting Officer | 3.7yrs | geen gegevens | 0.00041% $ 879.5k | |
| Senior VP & Chief Information Officer | 5.3yrs | geen gegevens | geen gegevens | |
| Chief Scientific Officer | 3.3yrs | geen gegevens | geen gegevens | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior VP & General Counsel | 6.8yrs | US$3.12m | 0.0032% $ 6.8m | |
| VP & Chief Communications Officer | 4.1yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Strategy & Corporate Development | 4.6yrs | geen gegevens | geen gegevens |
5.0yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TMO wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 15.1yrs | US$18.98m | 0.046% $ 98.5m | |
| Independent Lead Director | 18yrs | US$403.12k | 0.019% $ 40.4m | |
| Independent Director & Member of Scientific Advisory Board | 12.7yrs | US$325.72k | 0.0022% $ 4.7m | |
| Independent Director | 13.9yrs | US$365.72k | 0.0037% $ 8.0m | |
| Independent Director | 8.5yrs | US$345.72k | 0.0024% $ 5.2m | |
| Member of Scientific Advisory Board | no data | US$9.40m | geen gegevens | |
| Member of Scientific Advisory Board & Director | 15.5yrs | US$345.72k | 0.0022% $ 4.7m | |
| Member of Scientific Advisory Board | 7yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 5.2yrs | US$345.72k | 0.00040% $ 858.0k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 7.7yrs | US$353.19k | 0.0012% $ 2.5m |
12.7yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TMO zijn ervaren en ervaren (gemiddelde ambtstermijn van 12.7 jaar).